Search PubMed⌕ Search

Biomedical subjects

T Barth

Publications and source records attributed to T Barth.

At least 73 records · Page 4Linked to original sources
PubMed1987

Effects of oxytocin-related peptides on acute morphine tolerance: opposite actions by oxytocin and its receptor antagonists.

The hormonally and behaviorally active nonapeptide oxytocin (OXT), its behaviorally active N-terminal octapeptide desglycinamide9-OXT and Z-prolyl-D-leucine, a synthetic analog of the C-terminal prolyl7-leucine8 sequence, inhibited the development both of a moderate and of a strong tolerance to morphine. N-alpha-Acetyl-(2-0-methyltyrosine)-OXT and (penicillamine1-2-0-methyltyrosine)- lysine8-vasopressin, both OXT receptor antagonists, facilitated the development of a moderate morphine tolerance. The i.c.v. injection of either antagonist prevented the effects of i.c.v. and s.c. OXT treatment on the development of tolerance. The effect of desglycinamide9-OXT, but not that of Z-prolyl-D-leucine was also prevented by N-alpha-acetyl-(2-0-methyltyrosine)-OXT. It is concluded that OXT and desglycinamide9-OXT, but not Z-prolyl-D-leucine, attenuate morphine tolerance by affecting putative oxytocinergic binding sites in the mouse brain. The fact that i.c.v. injection of the receptor antagonist also blocked the effect of s.c. OXT treatment argues in favor of the possibility that a minor proportion of s.c. OXT (or behaviorally active fragments thereof) may reach central nervous system target sites.

Analgesia↗
PubMed1987

Effect of threonine in position 4 in oxytocin and vasotocin analogs on the time course of uterotonic response.

The substitution of glutamine by threonine in position 4 of oxytocin, deamino-oxytocin, deamino-1-carba-oxytocin, and deamino-6-carba-oxytocin was found to increase the elimination rate of all analogs examined from the uterine receptor compartment in rat. However, this substitution was without any effect on the time course of uterotonic response in the case of vasotocin and deamino-vasotocin. These results suggest that the topological relationships of the 4 and 8 positions may show an important effect on elimination rate of oxytocin and vasotocin analogs from the rat uterine compartment.

Animals↗
PubMed1985

On the blood-brain barrier to peptides: accumulation of labelled vasopressin, DesGlyNH2-vasopressin and oxytocin by brain regions.

After intracarotid injection of 125I-arginine vasopressin (AVP), 125I- or 3H-lysine vasopressin (LVP), 3H-DesGlyNH2-arginine vasopressin (DGAVP), and 125I- or 3H-oxytocin (OXT), the accumulation of radioactivity was determined in 13 to 18 brain regions and anterior pituitary in rats. Calculated extraction by tight capillary regions amounts to about 1-2% independently of the peptide doses injected (4 X 10(-4) to 5 X 10(-9) mol-1). This indicates a low but measurable extraction of labelled peptides which furthermore is nonsaturable. Among brain regions with tight capillaries, the extraction does not vary obviously. Blood-brain barrier (BBB)-free regions extract up to 30 fold more peptide than BBB-protected regions and the extraction varies considerably between individual regions. Within BBB-free regions, the peptides passed the leaky capillary endothelium, but there is no evidence for a penetration to deeper layers of the brain. It is concluded that endogenous blood-borne peptides cannot pass brain barriers in physiologically significant amounts. This does not exclude a possibility that passive transport of minute but effective amounts might occur if high pharmacological amounts of peptides are injected peripherally. But, as shown, none of the peptides studied possesses properties that favour its passage across the BBB.

Animals↗
PubMed1984

On the nature of the vasoreactivity depressing factor (VDF) in inflammation and anaphylaxis in the rat and mouse.

In anaphylactic paw edema the reactivity of blood vessels to norepinephrine in the isolated perfused hind legs of rats and mice is reduced. A vasoreactivity depressing factor was postulated and searched for. PAF-acether, histamine and lipoxygenase products were found as being possibly responsible for depression of the vascular reactivity.

4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyraz↗
PubMed1984

Nacartocin--analogue of oxytocin with enhanced natriuretic properties: natriuretic and hemodynamic characteristics.

Nacartocin, [2-p-ethylphenylalanine]deamino-6-carba-oxytocin, is almost three times more potent than oxytocin as a natriuretic agent. The natriuretic effect is mainly due to the inhibitory action of the peptide on tubular sodium resorption. Nacartocin decreased the blood pressure of anesthetized rats by the decrease of the total peripheral resistance which was greater than that observed after oxytocin administration. In conscious rats, Nacartocin caused a slight but prolonged increase of blood pressure.

Animals↗
PubMed1981

Comparison of antidiuretic and natriuretic effects of [8-lysine]vasopressin and [8-D-arginine]deaminovasopressin in conscious rats.

The relation between the duration of antidiuresis and sodium excretion and the route of administration of [8-lysine-vasopressin or [8-D-arginine]-deaminovasopressin to conscious rats was investigated. Both compounds were administered either intravenously through a chronically inserted catheter in the right jugular vein, or subcutaneously. The rats were then placed into individual metabolic cages and urine was collected quantitatively. Subcutaneous administration of both compounds resulted in a more prolonged antidiuretic response, lower sodium excretion and higher total urine osmolality. In order to achieve a comparable half-time antidiuresis, it was necessary to apply about 1000 times higher does of [8-lysine]vasopressin than those of [8D-arginine]deaminovasopressin. The relation between the duration of both antidiuresis and sodium excretion and the way of administration was, however, more pronounced in the case of [8-lysine]vasopressin. The excretion of potassium was increased after both compounds, the highest value being found after subcutaneous administration of [8-lysine]vasopressin.

Animals↗
PubMed1980

Effect of some oxytocin analogues on natriuresis in rats.

Non-anaesthetized rats were used for studying the relationship between the amount of sodium excreted and structural modifications of oxytocin molecule. Any change performed in position 4 (i.e. the glutamine residue) resulted in a decrease of natriuretic activity as compared to that of oxytocin. The analogues with modifications in the amino-terminal part of the molecule (e.g. substitution of the amino group in position 1 by hydrogen, or of the disulfide bond by a thioether group) resulted in a higher natriuretic effect than oxytocin.

Animals↗
PubMed1980

The term intrinsic sensitivity and its application to the vasopressor action of noradrenaline and vasopressin in arteriosclerotic rats.

The intrinsic sensitivity, i.s., as the quotient of the maximum of the cumulative dose-response curve of an agonist in a pathologically or otherwise changed target object to the maximum of the cumulative dose-response curve of the agonists in the normal target object, has been used to characterize the reaction ability for vasoconstriction of the blood vessel system of the isolated perfused hind legs of arteriosclerotic rats (pretreatment with vitamin D2) on the injection of noradrenaline (NA), 8-lysine-vasopressin (LVP), and a vasopressin preparation with an admixture of oxytocin (VA), respectively. I.s. was found to be 0.80 to NA, 0.32 to LVP, but 1.27 to VA. That means that reaction ability for vasoconstriction of the blood vessel system of vitamin D2-pretreated arteriosclerotic rats is decreased for certain agonists but is increased for others. pD2 value of NA was found to be 4.69 in normal rats and 4.85 in vitamin D2-pretreated rats. The respective data were 5.80 and 6.32 for LVP and 3.58 and 3.88 for VA. Comparing EAm in normal rats, the relation of NA, LVP, VA, prostaglandin F2 alpha, and angiotensin II was about 1 : 1 : 06 : 0.25 : 0.15.

Animals↗
PubMed1979

Vasopressin analogs: sedative properties and passive avoidance behavior in rats.

The effects of several types of vasopressin analogs that are considered to be resistant to some of the physiologically significant enzymatic systems were investigated utilizing rats trained in a passive avoidance task. Enhancement of avoidance latencies was observed 2, 7 and 13 days after the single learning trial when deamino-carbavasopressins, triglycyl-8-lysine-vasopressin or its des-glycinamide derivative, and deamino-D-arginine-vasopressin were given shortly after the learning trial in the dose of 1 microgram s.c. (8-L-Arginine)deamino-6-carba-vasopressin and (8-L-ornithine)deamino-6-carba-vasopressin were also active in the dose of 0.1 microgram. Lysine vasopressin and its des-glycinamide derivative failed to enhance avoidance latencies in part of the experiments if doses of 0.3--3 micrograms were administered and 7 or 13 day intervals were used between the learning and the test trials. Enhancement of avoidance latencies was also observed, if some of the peptides were injected 20 min but not 120 or 180 min before the test trial. Marked depression of exploratory behavior of rats in an open field was found after s.c. injections of low doses (1--3 micrograms kg-1) of deamino-carba-vasopressins. Higher doses (10--30 micrograms kg-1) induced sleep-like immobility not accompanied by ataxia or catalepsy.

Animals↗